Bank Julius Baer & Co. Ltd, Zurich Chimerix Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$4.58 - $6.8 $24,732 - $36,720	-5,400 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$5.23 - $7.18 $13,598 - $18,668	-2,600 Reduced 32.5%	5,400 $35,000
Q3 2021 Nov 12, 2021	SELL	$5.94 - $8.75 $65,340 - $96,250	-11,000 Reduced 57.89%	8,000 $50,000
Q2 2021 Jul 23, 2021	BUY	$7.54 - $9.79 $37,700 - $48,949	5,000 Added 35.71%	19,000 $152,000
Q1 2021 May 10, 2021	SELL	$4.76 - $11.25 $42,749 - $101,036	-8,981 Reduced 39.08%	14,000 $135,000
Q4 2020 Feb 24, 2021	SELL	$2.43 - $5.42 $46 - $102	-19 Reduced 0.08%	22,981 $111,000
Q4 2020 Feb 12, 2021	SELL	$2.43 - $5.42 $17,010 - $37,940	-7,000 Reduced 23.33%	23,000 $111,000
Q2 2020 Aug 12, 2020	BUY	$1.33 - $3.63 $10,062 - $27,464	7,566 Added 33.73%	30,000 $93,000
Q1 2020 May 13, 2020	BUY	$1.27 - $2.33 $28,491 - $52,271	22,434 New	22,434 $32,000

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.